SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

BrainStorm Cell Therapeutics Inc. (BCLI)

BCLI RSS Feed
Add BCLI Price Alert      Hide Sticky   Hide Intro
Moderator: early_retirement2
Search This Board: 
Last Post: 9/6/2017 3:03:11 PM - Followers: 118 - Board type: Free - Posts Today: 0

NASDAQ:BCLI

 

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as

  • Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease and Motor Neuron Disease)
    Multiple Sclerosis
    Parkinson’s Disease
    Huntington’s Disease

Our platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons. Our research efforts have shown that these MSC-NTF cells might be an effective tool for battling neurodegenerative diseases.

We believe

  • That delivery of these neurotrophic factors to injured or degenerating neurons can prolong their survival and improve their function.
    That MSCs, which possess beneficial properties including the ability to home to sites of injury and to dampen immune responses, represent the ideal biological delivery system for neurotrophic factors.

MSC-NTF cells have been shown in the laboratory and in animal models of neurodegenerative diseases to have a beneficial effect, and BrainStorm and our academic collaborators have published over 20 papers in leading scientific journals demonstrating NurOwn’s mechanism of action and efficacy. We invite you to view the Technology and Pipeline areas of our website to learn more.

NurOwn® in the Clinic

Human testing of MSC-NTF cells was initiated 2010 in ALS patients, a program that has now advanced to phase 2 clinical trials in the United States and Israel.  We have completed two single-arm clinical trials at Hadassah Medical Center in Jerusalem, in which a total of 26 ALS patients received MSC-NTF cells.  These studies established the safety profile of the cells and provided indications of a treatment benefit.

We recently completed a 48 patient randomized, double-blind, placebo-controlled phase 2 study of MSC-NTF cells at three prestigious academic medical centers in the United States.

NurOwn® has received Fast Track status from the US Food and Drug Administration (FDA) in ALS, and has additionally been granted Orphan Status for ALS by the FDA and the European Medicines Agency (EMA).


 

Technology

BrainStorm has developed a proprietary, stem cell based technology that delivers growth factors that can help neurons live longer at or near the site of injury or damage. We are developing this innovative therapy for the treatment of various neurodegenerative diseases. It has been tested in several animal models for various diseases, and has shown safety and promising signs of efficacy in clinical trials for amyotrophic lateral sclerosis.

Neurodegenerative Diseases and Stem Cell Research

Neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, multiple sclerosis, and many others afflict millions of people around the globe, but for the most part lack effective therapies. The need for therapies that can replace or repair dead, dying, stressed or damaged neurons has naturally led investigators to stem cell-based therapies.

In general, there are two distinct and potentially complimentary approaches to treating neurodegenerative diseases with cellular therapies – stem cells can be used to replace dead, damaged or dying neurons, or can be used to support damaged or dying neurons, through a variety of mechanisms including quieting the immune system and inflammation, secretion of growth factors, and differentiation into glial cells.

The first approach presents some important technical challenges, particularly in neurology – not only must one deliver neurons or cells that will turn into neurons, but one must insure those neurons are in the right place and making the right connections with other neurons in the central and/or peripheral nervous system, or with other tissues like muscle. Mesenchymal stem cells sclerosis, also called mesenchymal stromal cells, or MSCs, are an example of the second approach and have been used by researchers to treat a variety of conditions, including some neurodegenerative diseases.

We have made a major advancement on the use of mesenchymal stem cells with our NurOwn® technology platform.
 

NurOwn®

NurOwn® is a cell therapy platform that builds on the enormous research effort that has gone into developing mesenchymal stem cells (MSCs) as a treatment for human diseases. BrainStorm has taken MSCs a step further in developing a therapy customized for the treatment of neurodegenerative diseases.

Mesenchymal Stem Cells

MSCs are multipotent precursor cells found in many tissues, but most commonly obtained from the bone marrow, adipocytes or placenta. MSCs have been used in human studies since the 1990s, initially to enhance engraftment of bone marrow transplants, but eventually researchers discovered that MSCs are able to tamp down the immune system in a variety of different ways.

This led to their being studied as treatments for a variety of immune and inflammatory diseases, such as graft-versus-host disease, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis, and have been studied in cardiovascular disease, stroke, kidney disease, and many other areas – indeed there have been hundreds of clinical trials completed or ongoing for MSCs in various conditions. Prochymal® (remestemcel-L) is an MSC product that received conditional approval for the treatment of children with acute, steroid-refractory graft versus host disease in Canada and New Zealand.

How NurOwn® Makes a Better Cell

Where others leave off with MSCs, BrainStorm begins. Our patented NurOwn® technology takes MSCs and, by growing them in proprietary conditions, converts them into biological factories secreting a variety of neurotrophic factors (NTFs). NTFs are growth factors known to support the survival of neurons in a variety of conditions, and in animal models of many neurodegenerative diseases.

The NurOwn® technology was developed in the laboratories of Professor Dani Offen and the late Professor Eldad Melamed, at Tel Aviv University, and has been the subject of many publications. Our NTF-secreting MSCs (or, MSC-NTF cells) are designed specifically to treat neurodegenerative diseases by allowing us to deliver several NTFs at or close to the site of injury.

MSC-NTF cells also possess immunomodulatory characteristics and in some diseases, this may provide another mechanism for the cells providing a benefit. MSC-NTF cells secrete a variety of NTFs including Glial Derived Neurotrophic Factor (GDNF), Brain Derived Neurotrophic Factor (BDNF), Vascular Endothelial Growth Factor (VEGF), and Hepatocyte Growth Factor (HGF). Our cells can protect neurons from toxins and have been effective in animal models of ALS, sciatic nerve injury, Parkinson’s disease, multiple sclerosis, optic nerve ischemia and Huntington’s disease.

Stained cells ntfs

Over 60 patients with amyotrophic lateral sclerosis (ALS) have been treated with NurOwn® in clinical trials conducted in the United States and Israel, establishing an excellent safety and tolerability profile and demonstrating promising signs of efficacy.




 

Clinical Trials: http://www.brainstorm-cell.com/patients-caregivers/clinical-trials/

Pipeline: http://www.brainstorm-cell.com/pipeline/overview/

News/Events: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-news&nyo=0

Investors: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-irhome   

SEC Filings:  http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-sec                                             

 

 

Company Locations:

United States
Three University Plaza Drive, Suite 320
Hackensack, NJ 07601
201-488-0460

Israel
12 Bazel Street
POB 10019 Kiryat Aryeh
Petach Tikva
Israel 4900101
972-3-923-6384

 

 

 

 


 

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
BCLI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BCLI News: Proxy Statement (definitive) (def 14a) 09/14/2017 04:12:07 PM
BCLI News: Statement of Changes in Beneficial Ownership (4) 08/31/2017 04:09:50 PM
BCLI News: Statement of Changes in Beneficial Ownership (4) 08/23/2017 02:24:17 PM
BCLI News: Quarterly Report (10-q) 08/14/2017 04:45:07 PM
BCLI News: Statement of Changes in Beneficial Ownership (4) 07/26/2017 05:31:32 PM
PostSubject
#2404   from the July 21 PR about BCLI receiving early_retirement2 09/06/17 03:03:11 PM
#2403   you may want to do you research before early_retirement2 09/06/17 02:58:57 PM
#2402   You see the 10Q.. what a joke. Move TheBigWhale 08/25/17 12:08:23 AM
#2400   Does anyone know why this stock is in MFS 08/22/17 01:00:14 PM
#2399   good question.. so, over the past year, the early_retirement2 08/21/17 09:41:53 AM
#2398   question: if Israel initial patients start soon, how jfk 08/20/17 05:25:31 PM
#2397   August 16, 2017 - Conference call summary. click early_retirement2 08/16/17 02:04:15 PM
#2396   REMINDER - corporate update tomorrow, thinking it'll be early_retirement2 08/15/17 09:34:54 AM
#2395   NEWS - Earnings Call and corporate updates.. anyone early_retirement2 08/10/17 09:11:16 AM
#2394   NEWS - New Hire - this is a early_retirement2 08/07/17 09:49:29 AM
#2393   Don't get manipulated out of your shares. early_retirement2 08/03/17 03:06:22 PM
#2392   NEWS - Phase 3 Hospital early_retirement2 07/25/17 09:54:00 AM
#2391   nice.. excellent price to buy! my 5834 early_retirement2 07/24/17 10:27:34 AM
#2390   Bought a boat load in my 401k at GoldenMind 07/21/17 10:16:44 PM
#2389   NEWS - Huge.. step in the right direction. early_retirement2 07/21/17 09:16:48 AM
#2388   Very Very nice news today! The $16M won't cover murocman 07/21/17 08:33:24 AM
#2387   News - Phase 3 Hospital Agreements early_retirement2 07/18/17 09:04:27 AM
#2386   yea, me and other poster discussed this about early_retirement2 07/17/17 03:48:00 PM
#2385   Funding and potential dilution for Phase III is murocman 07/17/17 03:39:53 PM
#2384   Murocman - Unfortunately, that wasn't discussed. Today's early_retirement2 07/17/17 03:34:05 PM
#2383   Thank you for the summary! Any discussion murocman 07/17/17 02:34:01 PM
#2382   Just listened in on the webinar today, overall early_retirement2 07/17/17 02:22:14 PM
#2381   UPDATE - upcoming Phase 3. Review the link early_retirement2 07/07/17 11:20:48 PM
#2380   Nice work. I too have about $20,000 invested. early_retirement2 07/07/17 11:17:42 PM
#2379   Bought a bought load in my 401k. Lets GoldenMind 07/07/17 05:23:45 PM
#2378   free level 2 - www.bats.com/us/equities/overview/ insert-text-her early_retirement2 07/05/17 11:33:13 AM
#2377   nice bump up today as of 11:21am EST, early_retirement2 07/05/17 11:28:33 AM
#2376   Spideboy - Yea, no guidance has been given early_retirement2 07/05/17 11:04:01 AM
#2375   NEWS - Clinical Update early_retirement2 07/05/17 10:22:39 AM
#2374   Along with the impending start to Phase III, Spideyboy 06/30/17 12:38:38 PM
#2373   you're welcome, it's my pleasure. I enjoy early_retirement2 06/27/17 12:54:51 PM
#2372   Hi ER, Spideyboy 06/22/17 01:28:31 PM
#2371   For anyone who missed the update yesterday, there early_retirement2 06/22/17 09:27:09 AM
#2370   UPDATE BrainStorm to Provide Corporate Update at the BIO early_retirement2 06/14/17 09:16:40 AM
#2369   NEWS - Grant Awarded early_retirement2 06/13/17 09:27:42 AM
#2368   Thats a nice thought.Hopefully they can help both SOUTHGAS 05/22/17 04:43:59 PM
#2367   you're welcome. I like to provide info about early_retirement2 05/22/17 04:20:06 PM
#2366   Thanks for the info buddy.I am keeping an SOUTHGAS 05/22/17 03:12:50 PM
#2365   I would have thought there would be more early_retirement2 05/22/17 01:45:23 PM
#2364   Y W .Didnt look to affect it as SOUTHGAS 05/22/17 10:41:43 AM
#2363   thanks for the heads up, I did see early_retirement2 05/22/17 10:40:10 AM
#2362   Just saw news on otc markets saying they SOUTHGAS 05/16/17 03:05:12 AM
#2361   NEWS - 1Q 2017 Results early_retirement2 05/15/17 09:51:08 AM
#2360   NEWS - Presentation early_retirement2 05/01/17 09:23:09 AM
#2359   NEWS - Presentation early_retirement2 04/20/17 10:11:10 AM
#2358   NEWS - Autism Study early_retirement2 04/19/17 11:37:38 AM
#2357   The truth will out as always. Glad to see Spideyboy 04/17/17 03:29:19 PM
#2356   I think the market is figuring it out sudnwealth 04/17/17 02:36:16 PM
#2355   As mentioned in my earlier post, SA contribution Spideyboy 04/12/17 08:07:18 AM
#2354   I sincerely hope you do submit that as sudnwealth 04/11/17 07:42:40 PM
PostSubject